IDSA Releases Guidance On Treatment Of Antimicrobial-Resistant Infections
09 September 2020
Developed by a panel of six infectious diseases specialists with clinical and research expertise in the treatment of AMR bacterial infections, this first-in-a-series guidance addresses three groups of AMR Gram-negative bacteria that pose particular therapeutic challenges and have been designated as urgent or serious threats by CDC:
- Extended-spectrum β-lactamase producing Enterobacterales (ESBL-E)
- Carbapenem-resistant Enterobacterales (CRE)
- Difficult-to-treat resistance (DTR)-Pseudomonas aeruginosa
Further reading: IDSA
Author(s): IDSA
Effective Surveillance Healthy Patients
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!